Industry News & Media

The American Chemical Society recently organized a colloquium with the American Chemistry Council regarding opportunities and challenges in using advanced toxicity testing and risk assessment methods in a Modernized TSCA.  Learn more about the presentation, including slides and audio from the presenters.


Upcoming Industry-related Webinars

Each month the ACS New York Section's Chemical Marketing & Economics Group holds a luncheon and presentation.  You can join in for the presentation through a LIVE webcast, free to all current ACS members.  More information is available at the NYSCME Group website including how to register.

Join us on May 5, at 1 P.M. ET, to hear the insights of experts about the opportunities in  this exciting area. 

Federico Mennella, Managing Director & Head of Lincoln’s International Global Chemical practice. Led Chase's Chemical and Industrial M&A advisory . Worked at Peter J. Solomon, Deutsche Bank, McKinsey, Lazard, Oppenheimer and Arthur Andersen.

Renzo Merino, Analyst, Moody’s Sovereign Risk Group. Has covered the credit of the Inter-American Development Bank, Panama, Ecuador, USA, Canada, Australia, Hong Kong, South Africa, Brazil, Peru, and Venezuela. Country Risk Analyst at BMI.

George Rodriguez (moderator), strategy and innovation advisor. Served at Asahi Glass, Nagase, Pfizer and Union Carbide (Dow). Expertise in strategy, sales and marketing, and M&A in chemicals, biopharma, biofuels, bioplastics and Latin American operations.

James S. Rosenstein, Executive Director,Brazilian-American Chamber of Commerce. Served at ViS Research, Bentley Motors, Toyota, the European Bank for Reconstruction and Dev. and BNP. Fellow at Harvard University’s Advanced Leadership Initiative.

Michael King, PhD, is Michael King Jr is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mr King Jr was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology.

Nathan Tinker PhD, has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies.  Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group.  Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. 

Paul Pospisil, PhD, is a Senior Client Partner, Global Life Sciences at Korn Ferry. He recruits chief executive officer, chief business officer, head of research and development and other key executives. Was a co-founder of Aduro Capital LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics.

Michael King, PhD, is Michael King Jr is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mr King Jr was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology.

Nathan Tinker PhD, has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies.  Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group.  Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. 

Paul Pospisil, PhD, is a Senior Client Partner, Global Life Sciences at Korn Ferry. He recruits chief executive officer, chief business officer, head of research and development and other key executives. Was a co-founder of Aduro Capital LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics.


Driving Invention into Successful Innovation: 
Collaboration is Key

For more information, visit the Network & Learn website.


Learn from the best and brightest minds in chemistry.

Hundreds of webinars presented by subject matter experts in the chemical enterprise. LIVE every Thursday at 2pm ET!
Join Our Mailing List!


We have a topic of interest for every chemist. Go ahead, dive into these diverse categories and discover our growing archive of past webinars. 

Upcoming Webinars


Who Will Win the #ChemNobel? Predicting the 2017 Nobel Laureate(s) in Chemistry
September 27, 2017 @ 2-3pm ET

Can’t wait for this year’s announcement of the Nobel Prize in Chemistry on Oct. 4? Join C&EN and a panel of experts as they make their best guesses and cast your vote on who will claim the prize during this special webinar.  

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Spinal Muscular Atrophy: Novel Approaches for Treatment
Thursday, September 28, 2017 @ 2-3pm ET

Join Kevin Hodgetts of the Harvard Medical School as he discusses the pipeline of therapies for SMA which encompass four different strategies.

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Writing for the Lay Public: Engaging and Educating the General Population
October 5, 2017 @ 2-3pm ET

Join Kristin Sainani of the University of Stanford as she shares valuable tips for making your writing accessible to general audiences. 

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,

Metacommunication: Conveying Passion and Engaging Others
October 12, 2017 @ 2-3pm ET

Matt Grandbois of Dow Chemical shares how to tap into your inner scientific passion to create engaging storytelling experiences that will make your science and your data reach a larger audience.

Mary Ann Meador
Mary Ann Meador
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,
James Kennedy will explore the rise of chemophobia, an irrational fear of compounds perceived as ‘synthetic’,